Literature DB >> 6617729

Pharmacokinetics of the new analgesic, meptazinol, after oral and intravenous administration to volunteers.

H M Norbury, R A Franklin, D F Graham.   

Abstract

The pharmacokinetics of meptazinol (Meptid) have been studied in nine male volunteers after single and multiple oral administration of 200 mg tablets and also after a single 25 mg intravenous dose. Plasma concentrations of meptazinol were determined by HPLC using fluorescence detection. Drug absorption after oral dosage was rapid, peak plasma concentrations being reached between 0.25 and 2 h after drug administration. Subsequent elimination proceeded in an apparently mono-exponential fashion with a half-life of 2 h, although after intravenous dosage there was evidence of an initial rapid distributive phase. The mean total plasma clearance was 2.21/min and the mean apparent volume of distribution (Vd beta) was 4.99 l/min. The bioavailability ranged from 1.9 to 18.5% (mean = 8.7%) and was related to the rate of absorption. Multiple dosing, 6-hourly for 3 days, did not produce any accumulation above that predicted from a single dose. Plasma protein binding of the drug was 27.1% and did not vary over the therapeutic concentration range of 25 to 250 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6617729     DOI: 10.1007/bf00544019

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Studies on the metabolism of meptazinol, a new analgesic drug.

Authors:  R A Franklin; A Aldridge
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

2.  A comparison of the respiratory effects of meptazinol, pentazocine and morphine.

Authors:  C Jordan; J R Lehane; P J Robson; J G Jones
Journal:  Br J Anaesth       Date:  1979-06       Impact factor: 9.166

Review 3.  A review of the biological properties and metabolic disposition of the new analgesic agent, meptazinol.

Authors:  R J Stephens; J F Waterfall; R A Franklin
Journal:  Gen Pharmacol       Date:  1978

4.  Morphine metabolism in man.

Authors:  S F Brunk; M Delle
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

5.  Meperidine kinetics in man. Intravenous injection in surgical patients and volunteers.

Authors:  L E Mather; G T Tucker; A E Pflug; M J Lindop; C Wilkerson
Journal:  Clin Pharmacol Ther       Date:  1975-01       Impact factor: 6.875

6.  Determination of meptazinol in plasma by high-performance liquid chromatography with fluorescence detection.

Authors:  T Frost
Journal:  Analyst       Date:  1981-09       Impact factor: 4.616

7.  Routes of meptazinol conjugation in the neonate.

Authors:  P S Dowell; D M Pierce; R A Franklin; P J Robson; M B Jackson
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 8.  Buprenorphine: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-02       Impact factor: 9.546

9.  The influence of gastric emptying on plasma concentrations of the analgesic, meptazinol.

Authors:  R A Franklin
Journal:  Br J Pharmacol       Date:  1977-04       Impact factor: 8.739

10.  Double-blind crossover trial of oral meptazinol, pentazocine and placebo in the treatment of pain in the elderly.

Authors:  V Pearce; P J Robson
Journal:  Postgrad Med J       Date:  1980-07       Impact factor: 2.401

View more
  10 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 3.  Plasma protein binding of drugs in the elderly.

Authors:  S M Wallace; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

4.  Pharmacokinetics of meptazinol after parenteral administration in the elderly.

Authors:  G R Murray; R A Franklin; D F Graham; R R Lewis; M E Bolland
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Comparison of the effects of therapeutic doses of meptazinol and a dextropropoxyphene/paracetamol mixture alone and in combination with ethanol on ventilatory function and saccadic eye movements.

Authors:  N A Ali; R W Marshall; E M Allen; D F Graham; A Richens
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

Review 6.  Meptazinol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  B Holmes; A Ward
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

7.  The disposition of meptazinol after single and multiple intravenous administration to pregnant and non-pregnant women.

Authors:  G R Murray; D Evans; T Lind; R A Franklin; D F Graham
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

8.  The systemic availability of meptazinol in man after oral and rectal doses.

Authors:  G R Murray; O Petitjean; R A Franklin; D F Graham; J H Trouvin; C Jacquot
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Pharmacokinetics of meptazinol after single and multiple oral administration to elderly patients.

Authors:  H M Norbury; R A Franklin; D F Graham; B Sinha
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Enhanced oral bioavailability of meptazinol in cirrhosis.

Authors:  G G Birnie; G G Thompson; T Murray; G Watkinson; M J Brodie
Journal:  Gut       Date:  1987-03       Impact factor: 23.059

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.